Hashizume M, Hayakawa N, Mihara M
Product Research Department, Chugai Pharmaceutical Co. Ltd, Komakado, Gotemba, Shizuoka, Japan.
Rheumatology (Oxford). 2008 Nov;47(11):1635-40. doi: 10.1093/rheumatology/ken363. Epub 2008 Sep 11.
We investigated the influence of cytokines on the expression of RANK ligand (RANKL) in fibroblast-like synoviocytes from RA patients (RA-FLS).
RA-FLS were stimulated by IL-6, TNF-alpha, IL-17 and IL-1beta with or without soluble IL-6 receptor (sIL-6R) for 24 h. The expression of RANKL was measured by real-time PCR, western blotting and immunostaining. In proliferation assay, RA-FLS were cultured with cytokines for 3 days. RA-FLS were co-cultured with RAW cell in the presence of IL-6/sIL-6R for 3 days and then NFATc1 mRNA expression in RAW cells was examined. RA-FLS was cultured with parthenolide [PAR, signal transducer and activator of transcription (STAT) inhibitor] or PD98059 (PD, mitogen-activated protein kinase inhibitor) in the presence of IL-6/sIL-6R and then the influence of these drugs on phosphorylation of STAT3 and ERK1/2, and RANKL expression was examined.
RANKL expression was induced by IL-6/sIL-6R (but not IL-6 alone) and by IL-1beta. On the other hand, TNF-alpha and IL-17 did not induce RANKL expression, although TNF-alpha, IL-17 or IL-1beta stimulated cell growth and IL-6 production. However, in the presence of sIL-6R, TNF-alpha or IL-17 induced RANKL expression. By the co-culture of RA-FLS, NFATc1 mRNA expression was induced in RAW cells. Finally, IL-6/sIL-6R induced phosphorylation of STAT3 and ERK1/2 in RA-FLS, and was completely inhibited by PAR and PD, respectively. PAR completely inhibited IL-6/sIL-6R-induced RANKL expression, but PD did not.
IL-6/sIL-6R directly induced RANKL expression in RA-FLS and it is essential for RANKL induction by TNF-alpha and IL-17. Moreover, RANKL induction by IL-6/sIL-6R is mediated by the janus kinase/STAT signalling pathway.
我们研究了细胞因子对类风湿关节炎患者成纤维样滑膜细胞(RA-FLS)中核因子κB受体活化因子配体(RANKL)表达的影响。
用白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、白细胞介素-17(IL-17)和白细胞介素-1β(IL-1β)刺激RA-FLS 24小时,有无可溶性IL-6受体(sIL-6R)。通过实时聚合酶链反应(PCR)、蛋白质印迹法和免疫染色检测RANKL的表达。在增殖试验中,将RA-FLS与细胞因子共培养3天。在IL-6/sIL-6R存在的情况下,将RA-FLS与RAW细胞共培养3天,然后检测RAW细胞中活化T细胞核因子c1(NFATc1)mRNA的表达。在IL-6/sIL-6R存在的情况下,用小白菊内酯[PAR,信号转导子和转录激活子(STAT)抑制剂]或PD98059(PD,丝裂原活化蛋白激酶抑制剂)培养RA-FLS,然后检测这些药物对STAT3和细胞外信号调节激酶1/2(ERK1/2)磷酸化以及RANKL表达的影响。
IL-6/sIL-6R(而非单独的IL-6)和IL-1β诱导RANKL表达。另一方面,TNF-α和IL-17不诱导RANKL表达,尽管TNF-α、IL-17或IL-1β刺激细胞生长和IL-6产生。然而,在sIL-6R存在的情况下,TNF-α或IL-17诱导RANKL表达。通过RA-FLS的共培养,RAW细胞中诱导了NFATc1 mRNA表达。最后,IL-6/sIL-6R诱导RA-FLS中STAT3和ERK1/2的磷酸化,分别被PAR和PD完全抑制。PAR完全抑制IL-6/sIL-6R诱导的RANKL表达,但PD没有。
IL-6/sIL-6R直接诱导RA-FLS中RANKL表达,并且对于TNF-α和IL-17诱导RANKL表达至关重要。此外,IL-6/sIL-6R诱导RANKL表达是由janus激酶/STAT信号通路介导的。